Bristol Myers Squibb Underperforms Market, Q1 EPS Seen Falling 18.9%
Shares dropped 2.55% to $60.74, underperforming the S&P 500’s 0.57% loss after an 8.17% one-month gain versus sector’s 0.06% rise. Q1 EPS are projected at $1.46 (-18.9% YoY) on $10.86 billion revenue (-3.0% YoY), and stock trades at a forward P/E of 9.96 versus the industry average of 20.33.
1. Stock Performance
Bristol Myers Squibb closed at $60.74, down 2.55% after lagging the S&P 500’s 0.57% loss, the Dow’s 1.61% drop and the Nasdaq’s 0.26% decline. Over the past month, shares have risen 8.17%, outpacing the Medical sector’s 0.06% gain and the S&P 500’s 0.15% loss.
2. Earnings Forecast
For Q1, EPS are estimated at $1.46, a decline of 18.9% year-over-year, on revenue of $10.86 billion, down 3.0% year-over-year. Full-year expectations call for $6.26 EPS (+1.8% YoY) and $47.02 billion revenue (-2.4% YoY).
3. Valuation Metrics
The stock trades at a forward P/E of 9.96 compared with the industry average of 20.33, indicating a significant valuation discount. Its PEG ratio of 0.18 contrasts with the sector average of 1.51, suggesting growth expectations are priced conservatively.
4. Analyst Estimates
Consensus EPS estimates have increased by 3.3% over the last month, contributing to a Zacks Rank #3 (Hold) on the stock. The Medical - Biomedical and Genetics industry ranks 133 out of over 250 groups, placing it in the bottom 46% by average rank.